1.
Ter Arkh
; 93(9): 1132-1137, 2021 Sep 15.
Article
in Russian
| MEDLINE | ID: covidwho-1486854
ABSTRACT
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).